Eric Dow, administrator of Lone Star Endoscopy in Keller, Texas, a freestanding endoscopic ASC managed by Physicians Endoscopy, suggests following these five guidelines to improve turnover time between colonoscopies.
GI & Endoscopy
Brien Fausone, administrator of Michigan Endoscopy Center, a single-specialty GI ASC managed by Physicians Endoscopy, offers the following three tips to increase room turnover time.
Two physicians from the Northern Colorado Gastroenterology Clinic, based in Fort Collins, Colo., will begin treating patients at the Banner Health Medical Arts Centre of Windsor (Colo.), according to a report by the North Colorado Business Report.
Live endoscopy demonstrations, or courses that include demonstrations of endoscopic techniques in real time, can provide valuable educational opportunities, but can also raise questions regarding patient safety and ethics, according to the American Society for Gastrointestinal Endoscopy. To address these…
The American Society for Gastrointestinal Endoscopy has issued guidelines addressing ethnicity, gastrointestinal diseases and endoscopic procedures, according to an ASGE news release. The guidelines, developed by the ASGE's Standards of Practice Committee, appear in the June issue of GIE: Gastrointestinal…
Brien Fausone is the administrator of Michigan Endoscopy Center, a single-specialty GI ASC managed by Physicians Endoscopy.
Scientists from the Fraunhofer Institute for Photonic Microsystems in Dredsen, Germany, have developed a laser-based microscope head that fits on the end of an endoscope, which provides real-time in vivo diagnosis of cancer during endoscopy, according to a Fraunhofer news…
U.S. News & World Report has released its rankings of the top children's hospitals for gastroenterology.
The American College of Radiology has called on Congress to pass the Virtual Screening for Colorectal Cancer Act of 2010 (H.R. 5461), which would require the Centers for Medicare and Medicaid Services to provide coverage of screening computed tomography colonography,…
The U.S. Food and Drug Administration sent AstraZeneca a Complete Response Letter, rejecting a new drug application for the company's Axanum, according to an AstraZeneca news release.
